atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. The company's management team will engage in a fireside chat on Tuesday, September 10 at 4:30 P.M. EDT, along with 1x1 investor meetings.
Investors can access the fireside chat via a provided webcast link, and an archived replay will be available on the company's website for up to 90 days. This participation offers atai an opportunity to showcase its progress and strategies in transforming mental health treatment to a global investment audience.
atai Life Sciences (NASDAQ: ATAI), una compagnia biofarmaceutica in fase clinica focalizzata sui disturbi della salute mentale, ha annunciato la sua partecipazione al 26° Congresso Globale Annuale sugli Investimenti H.C. Wainwright a New York, NY, dal 9 all'11 settembre 2024. Il team di gestione dell'azienda parteciperà a un fireside chat martedì 10 settembre alle 16:30 EDT, insieme a incontri individuali con gli investitori.
Gli investitori potranno accedere al fireside chat tramite un link web fornito, e una registrazione archiviata sarà disponibile sul sito web dell'azienda per un massimo di 90 giorni. Questa partecipazione offre a atai l’opportunità di mostrare i suoi progressi e le strategie nel trasformare il trattamento della salute mentale a un pubblico di investitori globale.
atai Life Sciences (NASDAQ: ATAI), una compañía biofarmacéutica en etapa clínica enfocada en trastornos de salud mental, ha anunciado su participación en el 26° Congreso Global Anual de Inversiones H.C. Wainwright en Nueva York, NY, del 9 al 11 de septiembre de 2024. El equipo de gestión de la compañía participará en una charla informal el martes 10 de septiembre a las 4:30 P.M. EDT, junto con reuniones individuales con inversionistas.
Los inversionistas podrán acceder a la charla informal a través de un enlace de webcast proporcionado, y una grabación archivada estará disponible en el sitio web de la compañía durante un máximo de 90 días. Esta participación ofrece a atai la oportunidad de mostrar sus avances y estrategias en la transformación del tratamiento de la salud mental a una audiencia global de inversionistas.
atai Life Sciences (NASDAQ: ATAI), 정신 건강 장애에 초점을 맞춘 임상 단계의 생명공학 회사, 는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 회사의 경영진은 9월 10일 화요일 오후 4:30 EDT에 진행되는 파이어사이드 채팅에 참여하며, 1:1 투자자 회의도 진행합니다.
투자자들은 제공된 웹캐스트 링크를 통해 파이어사이드 채팅에 접근할 수 있으며, 회사 웹사이트에서 최대 90일 동안 아카이브된 재생을 이용할 수 있습니다. 이번 참여는 atai가 정신 건강 치료의 발전과 전략을 전 세계 투자자에게 보여줄 수 있는 기회를 제공합니다.
atai Life Sciences (NASDAQ: ATAI), une entreprise biopharmaceutique en phase clinique axée sur les troubles de la santé mentale, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright à New York, NY, du 9 au 11 septembre 2024. L'équipe de direction de l'entreprise participera à une discussion informelle le mardi 10 septembre à 16h30 EDT, ainsi qu'à des réunions individuelles avec des investisseurs.
Les investisseurs pourront accéder à la discussion informelle via un lien de webdiffusion fourni, et un enregistrement archivé sera disponible sur le site internet de l'entreprise pendant 90 jours maximum. Cette participation offre à atai l'opportunité de présenter ses progrès et ses stratégies pour transformer le traitement des troubles de la santé mentale à un public d'investisseurs mondial.
atai Life Sciences (NASDAQ: ATAI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf psychische Gesundheitsstörungen konzentriert, hat seine Teilnahme an der 26. Jahrestagung für Globale Investitionen von H.C. Wainwright in New York, NY, vom 9. bis 11. September 2024 bekannt gegeben. Das Management-Team des Unternehmens wird an einem Fireside-Chat am Dienstag, den 10. September um 16:30 Uhr EDT teilnehmen, zusammen mit 1:1 Investorengesprächen.
Investoren können über einen bereitgestellten Webcast-Link auf den Fireside-Chat zugreifen, und eine archivierte Wiederholung wird bis zu 90 Tage lang auf der Unternehmenswebsite verfügbar sein. Diese Teilnahme bietet atai die Möglichkeit, seine Fortschritte und Strategien zur Transformation der Behandlung psychischer Gesundheit einem globalen Investorenpublikum zu präsentieren.
- None.
- None.
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation:
Format: Fireside chat and 1x1 investor meetings
Date and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDT
Webcast link: Here
An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Contact Information
Investor Contact:
Media Contact:
FAQ
When is atai Life Sciences (ATAI) participating in the H.C. Wainwright Global Investment Conference?
What type of company is atai Life Sciences (ATAI)?
How can investors access atai Life Sciences' (ATAI) presentation at the H.C. Wainwright conference?
What is the format of atai Life Sciences' (ATAI) participation in the H.C. Wainwright conference?
